PharmaLogic Holdings has agreed to acquire Lantheus Holdings' contract development and manufacturing business and its Springfield, New Jersey radiopharmaceutical plant, the companies said on 9 November 2026. Terms were not disclosed.
Why PharmaLogic Holdings Corp. is buying Lantheus Holdings' CDMO business and Springfield, New Jersey facility
PharmaLogic, which runs more than 45 facilities in the US, Puerto Rico, Canada and Norway, said the site would make Agilera the first therapeutic CDMO with a transatlantic platform for radioligand therapies. Chief executive Etienne Montagut said the deal "strengthens Agilera's unique capabilities in radioligand therapies and expands our capacity in the U.S." Lantheus chief executive Mary Anne Heino said "PharmaLogic is the right long-term owner for the CDMO business and Springfield facility".
Deal terms and financing
No price was disclosed. Under a long-term supply agreement Agilera will manufacture lutetium Lu 177 dotatate, which Lantheus markets as BRAVNETSA, for Lantheus. The Springfield team will join Agilera on completion.
Regulatory approvals and timing
Closing is subject to applicable regulatory review and other customary conditions; no timetable was given, and the companies will operate independently until then.
Market context
Lantheus acquired the Springfield site with Evergreen Theragnostics in 2025 for about US$250m and is itself the subject of a pending takeover by Curium. Capacity for radioligand therapies remains scarce as more targeted radiopharmaceuticals reach the market.
